EGFR and non-small cell lung carcinoma: HERTHENA-Lung01, a phase II study of HER3-DXd in EGFR-mutated NSCLC patients with disease progression after EGFR TKI and platinum-baseed chemotherapy, demonstrated a promising ORR of 29.8% (95% CI, 23.9–36.2) with a CNS ORR of 33.3% (95% CI, 17.3–52.8) (NCT04619004) (45, 46).